Vaccines, Pneumococcal Conjugate Vaccine Clinical Trial
Official title:
A Phase 3, Open-label Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine Followed By 23-valent Pneumococcal Polysaccharide Vaccine In Recipients Of Allogeneic Hematopoietic Stem Cell Transplant Aged 2 Years And Older
People who have received an allogeneic hematopoetic stem cell transplant (HSCT) are more likely than other people to get ill from a germ called Streptococcus pneumoniae. Most people who have had a stem cell transplant are offered a vaccine called 23-valent pneumococcal polysaccharide vaccine (23vPS) to help protect against this germ. The purpose of this study is to evaluate the immune response in HSCT recipients who receive a 13 valent pneumococcal vaccine (13vPnC) followed by 23vPS.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00574795 -
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants
|
Phase 3 | |
| Completed |
NCT00269672 -
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
|
Phase 2 | |
| Completed |
NCT00580684 -
Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children
|
Phase 4 | |
| Completed |
NCT00500357 -
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
|
Phase 3 | |
| Completed |
NCT00581620 -
Study Evaluating Prevenar Immunogenicity in High Risk Children
|
Phase 4 | |
| Completed |
NCT00475033 -
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
|
Phase 3 | |
| Completed |
NCT00676091 -
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil
|
Phase 3 | |
| Completed |
NCT00683410 -
Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)
|
N/A |